Vontobel Holding Ltd. Acquires 241,440 Shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO)

Vontobel Holding Ltd. lifted its stake in Sangamo Therapeutics, Inc. (NASDAQ:SGMO) by 412.3% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 300,000 shares of the biopharmaceutical company’s stock after acquiring an additional 241,440 shares during the period. Vontobel Holding Ltd. owned approximately 0.14% of Sangamo Therapeutics worth $259,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. State Board of Administration of Florida Retirement System increased its holdings in shares of Sangamo Therapeutics by 61.1% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 62,345 shares of the biopharmaceutical company’s stock worth $42,000 after purchasing an additional 23,650 shares during the period. Cubist Systematic Strategies LLC bought a new position in Sangamo Therapeutics during the second quarter valued at about $67,000. Acadian Asset Management LLC increased its stake in Sangamo Therapeutics by 4.0% during the first quarter. Acadian Asset Management LLC now owns 4,943,260 shares of the biopharmaceutical company’s stock valued at $3,311,000 after acquiring an additional 192,385 shares during the period. Marshall Wace LLP raised its holdings in Sangamo Therapeutics by 56.3% in the 2nd quarter. Marshall Wace LLP now owns 576,219 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 207,476 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter worth approximately $89,000. Institutional investors own 56.93% of the company’s stock.

Analyst Ratings Changes

SGMO has been the topic of a number of research reports. HC Wainwright restated a “buy” rating and set a $5.00 price objective on shares of Sangamo Therapeutics in a research report on Tuesday. StockNews.com began coverage on shares of Sangamo Therapeutics in a report on Sunday, July 28th. They issued a “sell” rating on the stock. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $2.67.

Sangamo Therapeutics Trading Up 27.3 %

Shares of SGMO opened at $1.54 on Thursday. The stock has a 50 day simple moving average of $0.86 and a 200-day simple moving average of $0.66. The stock has a market cap of $320.66 million, a PE ratio of -1.12 and a beta of 1.23. Sangamo Therapeutics, Inc. has a 1 year low of $0.29 and a 1 year high of $1.77.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.01). Sangamo Therapeutics had a negative net margin of 2,033.69% and a negative return on equity of 273.25%. The company had revenue of $0.36 million for the quarter, compared to the consensus estimate of $11.40 million. On average, sell-side analysts forecast that Sangamo Therapeutics, Inc. will post -0.47 EPS for the current fiscal year.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.